Although new retinoids/HDAC inhibitors are now available for cancer treatment, it will be especially important to characterize the antileukemic in vivo effect of ATRA and the HDAC inhibitor VP to better understand the biological effects of these therapeutic strategies. This evidence concerns the gene HDAC9 and cancer.